Deutsche Bank
MLYS icon

Deutsche Bank’s Mineralys Therapeutics MLYS Stock Holding History

Deutsche Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
58,877
+18,761
+47% +$515K ﹤0.01% 2043
2026
Q1 		$1.09M Buy
40,116
+2,871
+8% +$84.2K ﹤0.01% 2134
2025
Q4 		$1.35M Buy
37,245
+6,315
+20% +$253K ﹤0.01% 2031
2025
Q3 		$1.17M Sell
30,930
-425,984
-93% -$9.21M ﹤0.01% 2074
2025
Q2 		$6.18M Buy
456,914
+160,899
+54% +$2.33M ﹤0.01% 1157
2025
Q1 		$4.7M Buy
296,015
+269,283
+1,007% +$3.1M ﹤0.01% 1276
2024
Q4 		$329K Buy
26,732
+10,264
+62% +$134K ﹤0.01% 2851
2024
Q3 		$199K Buy
16,468
+4,836
+42% +$58.5K ﹤0.01% 2926
2024
Q2 		$136K Buy
11,632
+3,299
+40% +$41.5K ﹤0.01% 3009
2024
Q1 		$108K Buy
+8,333
New +$103K ﹤0.01% 3136
2023
Q4 		– Sell
-5,678
Closed -$54K – 3675
2023
Q3 		$54K Hold
5,678
– – ﹤0.01% 3394
2023
Q2 		$96.8K Sell
5,678
-1,827
-24% -$27.3K ﹤0.01% 3288
2023
Q1 		$118K Buy
+7,505
New +$126K ﹤0.01% 3255

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Deutsche Bank's MLYS Position: Q2 2026 in Review

Deutsche Bank increased its Mineralys Therapeutics (MLYS) stake by 47% in Q2 2026, buying an estimated $515K and bringing the position to 58,877 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Deutsche Bank first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.18M in Q2 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Deutsche Bank held 58,877 shares of Mineralys Therapeutics worth $1.59M as of Q2 2026.
  • Deutsche Bank bought 18,761 Mineralys Therapeutics shares in Q2 2026, an estimated $515K.
  • Mineralys Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2043 holding.
  • Deutsche Bank first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Deutsche Bank's Mineralys Therapeutics position peaked at $6.18M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.